about
Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational studyEmerging drugs for Guillain-Barré syndromeGuillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosisIVIG treatment and prognosis in Guillain-Barré syndromeInterventions for fatigue in peripheral neuropathyIntravenous immunoglobulin for Guillain-Barré syndromeCorticosteroids for Guillain-Barré syndromeImmunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathyIntravenous immunoglobulin for Guillain-Barré syndromeIntravenous immunoglobulin for Guillain-Barré syndromeImmunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathyCorticosteroids for Guillain-Barré syndromeInterventions for fatigue in peripheral neuropathyIntravenous immunoglobulin for Guillain-Barré syndromeCytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathyCorticosteroids for Guillain-Barré syndromeThe epidemiology and risk factors of chronic polyneuropathyGuillain-Barré syndromeClinical features, pathogenesis, and treatment of Guillain-Barré syndromeHealth-related quality of life in Guillain-Barré syndrome patients: a systematic reviewHearing in adults with Pompe diseasePhenotypical variation within 22 families with Pompe disease.Host factors determine anti-GM1 response following oral challenge of chickens with Guillain-Barré syndrome derived Campylobacter jejuni strain GB11.Increased aortic stiffness and blood pressure in non-classic Pompe disease.Antibodies to heteromeric glycolipid complexes in Guillain-Barré syndrome.Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy.Immunotherapy for Guillain-Barré syndrome.Challenges of clinical trial design when there is lack of clinical equipoise: use of a response-conditional crossover designThe quick motor function test: a new tool to rate clinical severity and motor function in Pompe patients.Safety and efficacy of exercise training in adults with Pompe disease: evalution of endurance, muscle strength and core stability before and after a 12 week training programHospital Admissions, Transfers and Costs of Guillain-Barré Syndrome.Treatment of Guillain-Barré syndrome and CIDP.The natural course of non-classic Pompe's disease; a review of 225 published cases.Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study.Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up.Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational studyDetermination of pain and response to methylprednisolone in Guillain-Barré syndrome.Fatigue: an important feature of late-onset Pompe disease.Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy.
P50
Q21202855-F08782B1-4BBD-4970-AF0C-04D7513F5107Q22241376-6DADD617-636F-4620-9C7D-A8FB85C0230DQ22251013-FDE87C89-8926-4E27-B3A3-55906CC996A4Q22252627-5DD790DA-9924-4D71-AE09-3385807B7C8FQ24187233-5DC2C7D7-F06C-498F-95AD-04A0821CB0CAQ24193522-AB425504-641E-405B-8FDB-6BE13664EEC1Q24201413-A00B19BC-7423-4374-849D-4D986909262AQ24201954-2F9952A2-4019-4BD1-8817-6BE685FC731BQ24202100-4A9E7502-8F43-4767-AAFC-2E0730FFD7E3Q24234992-23FAA6F2-F82A-4CC2-8A8E-47B3E382E0A9Q24236599-5297A69D-F035-4CA6-8658-1F9F8974896EQ24240016-733A0EB6-1A33-4D92-81A7-2A5FCF8D59A0Q24240807-5EDA5251-415B-4A74-9630-7A6FB90F814DQ24244575-250B9DEB-204F-41CE-BD0B-8F51A959777FQ24246094-96D77341-91B1-4C03-BB24-B03D5717C153Q24246424-39EFC96B-11BB-416B-A4F7-EA7B0CE52B16Q26772148-BCDD16C7-681B-4AB4-929A-C9821FEE898CQ28273931-7577B3EC-A270-4891-AECF-AE50801F6FB3Q28296591-DDA08697-658A-4831-B454-765B975FF52EQ28306474-79D57614-4BEA-4F67-8631-8C4C0FF7E0C5Q30470326-517AB3D8-5E1A-45B4-B75A-6DD57EA53DB2Q30558083-7EEFE776-0F64-4495-9CD8-8CE4E2DEE359Q33546391-050C8270-8D7A-426D-82E4-6F3A876C8C0EQ33579864-5CADA353-1B65-45C1-8F8C-A6EBAD1891B7Q35072720-E1EBF2AF-318F-4DBB-9FD7-D050A51260ADQ35102705-5DF5E47C-F35B-4953-A1B0-755489FF2796Q35640543-0354E938-441A-4166-BB6D-452D05975F53Q35714185-00831523-EF9B-4B80-B661-375E14C3A952Q35754407-C97F578E-B6EB-4086-8A19-25BC8FA26458Q35863802-924627B9-A25A-484D-A767-E99B1F81FCBEQ35918443-D62C392C-8F28-4F05-BA14-11BF7BAB6D3BQ36164126-B8717A9D-DA32-4012-9CA3-FE681E77DFEAQ36245480-AC0AFE58-111A-46B4-A129-83644994999EQ36365583-DAB89B8F-4992-42C1-B6D0-E0AB75D303CDQ36459627-EF64713D-9BCE-4EAF-A0D4-BE1752ED919EQ36582225-72AC7774-341A-44B0-ACCB-4C1AA36C903DQ36758919-9FF19BC4-9802-4DDF-BBC0-854C2972B0EEQ37424369-5B0F4AB3-B796-4248-A311-7701567F1FAFQ37425960-D847E471-1380-4691-A1DD-C8D5629AA1CCQ37507924-1F85A0A2-4B9C-4687-82BA-15810AB2496E
P50
subject
name
Pieter A van Doorn
@ast
Pieter A van Doorn
@en
Pieter A van Doorn
@nl
type
label
Pieter A van Doorn
@ast
Pieter A van Doorn
@en
Pieter A van Doorn
@nl
prefLabel
Pieter A van Doorn
@ast
Pieter A van Doorn
@en
Pieter A van Doorn
@nl
P1006
P214
P1006
P214
P31
P735
P7859
viaf-284992512